The European Medicines Agency’s (EMA) human medicines committee (CHMP) today announced recommendations for the approval of ...

French pharma major Sanofi (Euronext: SAN) today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD).

US pharma major Johnson & Johnson has reported positive top-line Phase III data showing that a dual bispecific antibody ...

A UK-headquartered clinical-stage biopharmaceutical company developing once-weekly oral GLP-1 and amylin analogs for obesity ...

Spanish medical dermatology company Almirall (BME: ALM) has reported first-half 2026 net sales of 602.7 million euros ($687.1 ...

A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...

A clinical‑stage biopharma company based California, focused on therapies for CNS disorders. Founded by experts in psychiatry and neuroscience to target neural circuits causally linked to disease, the ...

39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...

French ophthalmology specialist Théa has entered into a long-term manufacturing partnership with French CDMO Unither Pharmaceuticals to build a dedicated sterile eye care production facility in the ...

US RNA medicines company Arrowhead Pharmaceuticals (Nasdaq: ARWR) saw its shares rise about 19% after reporting positive top-line results from two pivotal Phase III studies of plozasiran in severe ...

A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the ...